We have recently identified a somatic mutation in the gene encoding Akt1 resulting in a glutamic acid to lysine substitution at amino acid 17 (E17K) in a subset of NSCLC patients with increased Akt activity [20]. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.